Kallistatin is a new inhibitor of angiogenesis and tumor growth.

Kallistatin is a unique serine proteinase inhibitor (serpin) and a heparin-binding protein. It has been localized in vascular smooth muscle cells and endothelial cells of human blood vessels, suggesting that kallistatin may be involved in the regulation of vascular function. Our previous study showed that kallistatin plays a role in neointima hyperplasia. In this study, we investigated the potential role of kallistatin in angiogenesis in vitro and in vivo. Purified human kallistatin significantly inhibited vascular endothelial growth factor (VEGF)- or basic fibroblast growth factor (bFGF)-induced proliferation, migration, and adhesion of cultured endothelial cells. Kallistatin attenuated VEGF- or bFGF-induced capillary density and hemoglobin content in subcutaneously implanted Matrigel plugs in mice. To further investigate the role of kallistatin in angiogenesis, we prepared adenovirus carrying the human kallistatin cDNA (Ad.HKBP) and evaluated the effect of kallistatin gene delivery on spontaneous angiogenesis in a rat model of hind-limb ischemia. Local kallistatin gene delivery significantly reduced capillary formation and regional blood perfusion recovery in the ischemic hind limb after removal of the femoral artery. Furthermore, a single intratumoral injection of Ad.HKBP into pre-established human breast tumor xenografts grown in athymic mice resulted in significant inhibition of tumor growth. CD31 immunostaining of tumor sections showed a decreased number of blood vessels in the kallistatin-treated group as compared to the control. These results demonstrate a novel role of kallistatin in the inhibition of angiogenesis and tumor growth.

[1]  W. T. Chen,et al.  Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. , 1998, Circulation research.

[2]  S. Woo,et al.  Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  K. Bhoola,et al.  Kallikrein and kinin receptor genes. , 2000, Pharmacology & therapeutics.

[4]  L. Chao,et al.  Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. , 1996, Current eye research.

[5]  William Arbuthnot Sir Lane,et al.  Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. , 1999, Science.

[6]  H. Tschesche,et al.  Tissue kallikrein effectively activates latent matrix degrading metalloenzymes. , 1989, Advances in experimental medicine and biology.

[7]  C. Soria,et al.  Activation of the 92 kDa type IV collagenase by tissue kallikrein , 1993, Journal of cellular physiology.

[8]  L. Chao,et al.  A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. , 2001, The American journal of pathology.

[9]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[10]  M. Steurer,et al.  Angiogenesis as a target for tumor treatment. , 1997, Oncology.

[11]  P. Huang,et al.  Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. , 1998, The Journal of clinical investigation.

[12]  P. Opolon,et al.  Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice , 1998, Gene Therapy.

[13]  L. Chao,et al.  Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. , 1996, The Journal of laboratory and clinical medicine.

[14]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[15]  L. Chao,et al.  Identification of a Major Heparin-binding Site in Kallistatin* , 2001, The Journal of Biological Chemistry.

[16]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[17]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[18]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[19]  D. Scherman,et al.  Antiangiogenic Effect of Interleukin-10 in Ischemia-Induced Angiogenesis in Mice Hindlimb , 2000, Circulation research.

[20]  L. Chao,et al.  Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. , 1997, Investigative ophthalmology & visual science.

[21]  J. Ji.  Pigment epithelium derived factor:a potent inhibitor of angiogenesis , 2002 .

[22]  L. Chao,et al.  Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. , 1997, Life sciences.

[23]  J. Potempa,et al.  The serpin superfamily of proteinase inhibitors: structure, function, and regulation. , 1994, The Journal of biological chemistry.

[24]  S. Soker,et al.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. , 1992, The Journal of biological chemistry.

[25]  R. Auerbach,et al.  Angiogenesis inhibition: a review. , 1994, Pharmacology & therapeutics.

[26]  L. Chao,et al.  Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. , 1990, The Journal of biological chemistry.

[27]  C. Newgard,et al.  Use of recombinant adenovirus for metabolic engineering of mammalian cells. , 1994, Methods in cell biology.

[28]  K. Kinzler,et al.  A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Iozzo,et al.  Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. , 2001, The Journal of clinical investigation.

[30]  O. Volpert,et al.  Maspin is an angiogenesis inhibitor , 2000, Nature Medicine.

[31]  T. Sasaki,et al.  Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. , 2000, Blood.

[32]  J. Isner,et al.  Targeting Kinin B1 Receptor for Therapeutic Neovascularization , 2002, Circulation.

[33]  L. Chao,et al.  Kallistatin is a potent new vasodilator. , 1997, The Journal of clinical investigation.

[34]  R Bicknell,et al.  Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. , 1997, The Journal of clinical investigation.

[35]  Anthony J. Guidi,et al.  Microvessel density and distribution in ductal carcinoma in situ of the breast. , 1994, Journal of the National Cancer Institute.

[36]  L. Chao,et al.  Identification of a new tissue-kallikrein-binding protein. , 1986, The Biochemical journal.

[37]  S. Brem,et al.  Angiogenesis as a marker of preneoplastic lesions of the human breast , 1978, Cancer.

[38]  L. Chao,et al.  Kallistatin stimulates vascular smooth muscle cell proliferation and migration in vitro and neointima formation in balloon-injured rat artery. , 2000, Circulation research.

[39]  S. Janciauskiene.  Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. , 2001, Biochimica et biophysica acta.

[40]  R. Timpl,et al.  Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin , 1999, The EMBO journal.

[41]  J. Isner,et al.  Mouse model of angiogenesis. , 1998, The American journal of pathology.

[42]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[43]  L. Chao,et al.  Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. , 1992, The Journal of biological chemistry.

[44]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[45]  L. Chao,et al.  Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats. , 1995, Hypertension.

[46]  Y. Liang,et al.  Tissue Kallikrein-binding Protein Reduces Blood Pressure in Transgenic Mice* , 1996, The Journal of Biological Chemistry.

[47]  A. Passaniti,et al.  A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[48]  SatoshiTakeshita,et al.  Endothelium-Dependent Relaxation of Collateral Microvessels After Intramuscular Gene Transfer of Vascular Endothelial Growth Factor in a Rat Model of Hindlimb Ischemia , 1998 .

[49]  P. Opolon,et al.  Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  L. Chao,et al.  Localization and Expression of Tissue Kallikrein and Kallistatin in Human Blood Vessels , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[51]  L. Chao,et al.  Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. , 1993, The Journal of biological chemistry.